Los Angeles Capital Management LLC Increases Stake in IQVIA Holdings Inc. $IQV

Los Angeles Capital Management LLC raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 3.5% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 179,645 shares of the medical research company’s stock after purchasing an additional 6,118 shares during the period. Los Angeles Capital Management LLC’s holdings in IQVIA were worth $38,888,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Claret Asset Management Corp lifted its holdings in IQVIA by 1.1% in the 3rd quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock valued at $860,000 after purchasing an additional 49 shares in the last quarter. Leonard Rickey Investment Advisors P.L.L.C. lifted its holdings in IQVIA by 3.3% in the 4th quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock valued at $409,000 after purchasing an additional 58 shares in the last quarter. Brookstone Capital Management lifted its holdings in IQVIA by 2.2% in the 4th quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock valued at $661,000 after purchasing an additional 63 shares in the last quarter. Private Advisor Group LLC raised its holdings in shares of IQVIA by 1.0% during the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after acquiring an additional 63 shares during the period. Finally, Keybank National Association OH raised its holdings in shares of IQVIA by 0.7% during the 4th quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock worth $2,052,000 after acquiring an additional 67 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

IQV stock opened at $183.56 on Monday. The business has a 50 day moving average price of $172.12 and a 200 day moving average price of $194.79. The stock has a market cap of $30.64 billion, a price-to-earnings ratio of 22.75, a PEG ratio of 1.57 and a beta of 1.21. IQVIA Holdings Inc. has a fifty-two week low of $147.62 and a fifty-two week high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a share buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Royal Bank Of Canada assumed coverage on IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target on the stock. Morgan Stanley set a $225.00 price target on IQVIA in a report on Thursday, May 7th. HSBC set a $210.00 price target on IQVIA in a report on Wednesday. Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Truist Financial reduced their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $224.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.